Román Martinez, Manuel
García Aguilar, Eva
Martin Vílchez, Samuel
González García, Javier
Luquero-Bueno, Sergio
Camargo-Mamani, Paola
Mejia-Abril, Gina
García-Castro, Laura
de Miguel-Cáceres, Alejandro
Saz-Leal, Paula
Abad-Santos, Francisco
Nieto Magro, Concepcion
Ochoa Mazarro, Dolores http://orcid.org/0000-0002-1265-6600
Funding for this research was provided by:
ITF Research Pharma S.L.U.
Article History
Accepted: 29 June 2022
First Online: 2 August 2022
Declarations
:
: The study was funded by the sponsor ITF Research Pharma S.L.U.
: F. Abad-Santos, D. Ochoa and M. Román have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. E. García Aguliar, J. González García, P. Saz-Leal and C. Nieto Magro are employees of ITF Research Pharma S.L.U. The rest of the authors declare that they have no conflicts of interest.
: The study was reviewed and approved by the Research Ethics Committee of the Hospital Universitario de La Princesa in Madrid on 13 May 2020.
: Qualified researchers or institutions may request data that support the findings of this study from the corresponding author, and the study sponsor.
: Not applicable.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: MR, DO, SMV, and SL-B were involved in study design and supervised the work. PC-M, GM-A, LG-C and AdM-C participated in data collection and sample processing. MR and DO analyzed experimental data. PS-L, FA-S, CNM, DO, EGA and SMV contributed to data interpretation and to the writing of the manuscript. All authors contributed to the interpretation of study data and critically reviewed and approved the final version of the manuscript.